These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31265459)

  • 1. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results.
    Baker MA; Baer B; Kulldorff M; Zichittella L; Reindel R; DeLuccia S; Lipowicz H; Freitas K; Jin R; Yih WK
    PLoS Med; 2019 Jul; 16(7):e1002844. PubMed ID: 31265459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
    Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
    Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines.
    Kamidani S; Panagiotakopoulos L; Licata C; Daley MF; Yih WK; Zerbo O; Tseng HF; DeSilva MB; Nelson JC; Groom HC; Williams JTB; Hambidge SJ; Donahue JG; Belay ED; Weintraub ES
    Pediatrics; 2022 Dec; 150(6):. PubMed ID: 36349537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children.
    Yung CF; Ma X; Cheung YB; Oh BK; Soh S; Thoon KC
    Sci Rep; 2019 Oct; 9(1):14705. PubMed ID: 31604998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006.
    Abrams JY; Weintraub ES; Baggs JM; McCarthy NL; Schonberger LB; Lee GM; Klein NP; Belongia EA; Jackson ML; Naleway AL; Nordin JD; Hambidge SJ; Belay ED
    Vaccine; 2015 Jan; 33(2):382-7. PubMed ID: 25444786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake.
    Schuck-Paim C; Taylor R; Lindley D; Klugman KP; Simonsen L
    Vaccine; 2013 Dec; 31(50):5983-8. PubMed ID: 24144470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine.
    Center KJ; Hansen JR; Lewis E; Fireman BH; Hilton B
    Pediatr Infect Dis J; 2009 May; 28(5):438-40. PubMed ID: 19319016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine.
    Stockwell MS; Broder K; LaRussa P; Lewis P; Fernandez N; Sharma D; Barrett A; Sosa J; Vellozzi C
    JAMA Pediatr; 2014 Mar; 168(3):211-9. PubMed ID: 24395025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
    Baker MA; Nguyen M; Cole DV; Lee GM; Lieu TA
    Vaccine; 2013 Dec; 31 Suppl 10():K98-112. PubMed ID: 24331080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Baker MA; Jankosky C; Yih WK; Gruber S; Li L; Cocoros NM; Lipowicz H; Coronel-Moreno C; DeLuccia S; Lin ND; McMahill-Walraven CN; Menschik D; Selvan MS; Selvam N; Chen Tilney R; Zichittella L; Lee GM; Kawai AT
    Vaccine; 2020 Feb; 38(9):2166-2171. PubMed ID: 32019703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
    Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
    Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of pneumococcal vaccines at the time of sequential schedule: data from surveillance of adverse events following 13-valent conjugated pneumococcal and 23-valent polysaccharidic pneumococcal vaccines in newborns and the elderly, in Puglia (Italy), 2013-2020.
    Di Lorenzo A; Martinelli A; Bianchi FP; Scazzi FL; Diella G; Tafuri S; Stefanizzi P
    Ann Ig; 2023; 35(4):459-467. PubMed ID: 36477097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.